162 related articles for article (PubMed ID: 38352877)
1. The combination of IL-2 nanoparticles and Palbociclib enhances the anti-tumor immune response for colon cancer therapy.
Wang D; Wang X; Zhang Y; Yu L; An J; Wang X; Huang Y; Han X
Front Immunol; 2024; 15():1309509. PubMed ID: 38352877
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics, biodistribution and in vivo efficacy of cisplatin loaded poly(L-glutamic acid)-g-methoxy poly(ethylene glycol) complex nanoparticles for tumor therapy.
Yu H; Tang Z; Zhang D; Song W; Zhang Y; Yang Y; Ahmad Z; Chen X
J Control Release; 2015 May; 205():89-97. PubMed ID: 25529533
[TBL] [Abstract][Full Text] [Related]
3. Combination of cyclin-dependent kinase and immune checkpoint inhibitors for the treatment of bladder cancer.
Long Q; Ma AH; Zhang H; Cao Z; Xia R; Lin TY; Sonpavde GP; de Vere White R; Guo J; Pan CX
Cancer Immunol Immunother; 2020 Nov; 69(11):2305-2317. PubMed ID: 32506263
[TBL] [Abstract][Full Text] [Related]
4. Bufalin-loaded mPEG-PLGA-PLL-cRGD nanoparticles: preparation, cellular uptake, tissue distribution, and anticancer activity.
Yin P; Wang Y; Qiu Y; Hou L; Liu X; Qin J; Duan Y; Liu P; Qiu M; Li Q
Int J Nanomedicine; 2012; 7():3961-9. PubMed ID: 22888239
[TBL] [Abstract][Full Text] [Related]
5. Chemo-immunotherapy with oxaliplatin and interleukin-7 inhibits colon cancer metastasis in mice.
Gou HF; Huang J; Shi HS; Chen XC; Wang YS
PLoS One; 2014; 9(1):e85789. PubMed ID: 24465710
[TBL] [Abstract][Full Text] [Related]
6. Palbociclib synergizes with BRAF and MEK inhibitors in treatment naïve melanoma but not after the development of BRAF inhibitor resistance.
Martin CA; Cullinane C; Kirby L; Abuhammad S; Lelliott EJ; Waldeck K; Young RJ; Brajanovski N; Cameron DP; Walker R; Sanij E; Poortinga G; Hannan RD; Pearson RB; Hicks RJ; McArthur GA; Sheppard KE
Int J Cancer; 2018 May; 142(10):2139-2152. PubMed ID: 29243224
[TBL] [Abstract][Full Text] [Related]
7. Simultaneous blockade of multiple immune system inhibitory checkpoints enhances antitumor activity mediated by interleukin-15 in a murine metastatic colon carcinoma model.
Yu P; Steel JC; Zhang M; Morris JC; Waldmann TA
Clin Cancer Res; 2010 Dec; 16(24):6019-28. PubMed ID: 20924130
[TBL] [Abstract][Full Text] [Related]
8. Cisplatin nanoparticles possess stronger anti-tumor synergy with PD1/PD-L1 inhibitors than the parental drug.
Shen N; Yang C; Zhang X; Tang Z; Chen X
Acta Biomater; 2021 Nov; 135():543-555. PubMed ID: 34400305
[TBL] [Abstract][Full Text] [Related]
9. Targeting PARP-1 with metronomic therapy modulates MDSC suppressive function and enhances anti-PD-1 immunotherapy in colon cancer.
Ghonim MA; Ibba SV; Tarhuni AF; Errami Y; Luu HH; Dean MJ; El-Bahrawy AH; Wyczechowska D; Benslimane IA; Del Valle L; Al-Khami AA; Ochoa AC; Boulares AH
J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33495297
[TBL] [Abstract][Full Text] [Related]
10. TransCon IL-2 β/γ: a novel long-acting prodrug with sustained release of an IL-2Rβ/γ-selective IL-2 variant with improved pharmacokinetics and potent activation of cytotoxic immune cells for the treatment of cancer.
Rosen DB; Kvarnhammar AM; Laufer B; Knappe T; Karlsson JJ; Hong E; Lee YC; Thakar D; Zúñiga LA; Bang K; Sabharwal SS; Uppal K; Olling JD; Kjaergaard K; Kurpiers T; Schnabel M; Reich D; Glock P; Zettler J; Krusch M; Bernhard A; Heinig S; Konjik V; Wegge T; Hehn Y; Killian S; Viet L; Runz J; Faltinger F; Tabrizi M; Abel KL; Breinholt VM; Singel SM; Sprogøe K; Punnonen J
J Immunother Cancer; 2022 Jul; 10(7):. PubMed ID: 35817480
[TBL] [Abstract][Full Text] [Related]
11. Combination Immunotherapy With LIGHT and Interleukin-2 Increases CD8 Central Memory T-Cells In Vivo.
Fernandez MF; Qiao G; Tulla K; Prabhakar BS; Maker AV
J Surg Res; 2021 Jul; 263():44-52. PubMed ID: 33631377
[TBL] [Abstract][Full Text] [Related]
12. Cisplatin Loaded Poly(L-glutamic acid)-g-Methoxy Poly(ethylene glycol) Complex Nanoparticles for Potential Cancer Therapy: Preparation, In Vitro and In Vivo Evaluation.
Yu H; Tang Z; Li M; Song W; Zhang D; Zhang Y; Yang Y; Sun H; Deng M; Chen X
J Biomed Nanotechnol; 2016 Jan; 12(1):69-78. PubMed ID: 27301173
[TBL] [Abstract][Full Text] [Related]
13. Pre-existing effector T-cell levels and augmented myeloid cell composition denote response to CDK4/6 inhibitor palbociclib and pembrolizumab in hormone receptor-positive metastatic breast cancer.
Egelston C; Guo W; Yost S; Lee JS; Rose D; Avalos C; Ye J; Frankel P; Schmolze D; Waisman J; Lee P; Yuan Y
J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33757987
[TBL] [Abstract][Full Text] [Related]
14. Improved immunotherapy of a recombinant carcinoembryonic antigen vaccinia vaccine when given in combination with interleukin-2.
McLaughlin JP; Schlom J; Kantor JA; Greiner JW
Cancer Res; 1996 May; 56(10):2361-7. PubMed ID: 8625312
[TBL] [Abstract][Full Text] [Related]
15. Role of integrated cancer nanomedicine in overcoming drug resistance.
Iyer AK; Singh A; Ganta S; Amiji MM
Adv Drug Deliv Rev; 2013 Nov; 65(13-14):1784-802. PubMed ID: 23880506
[TBL] [Abstract][Full Text] [Related]
16. OX40 ligation enhances primary and memory cytotoxic T lymphocyte responses in an immunotherapy for hepatic colon metastases.
Pan PY; Zang Y; Weber K; Meseck ML; Chen SH
Mol Ther; 2002 Oct; 6(4):528-36. PubMed ID: 12377195
[TBL] [Abstract][Full Text] [Related]
17. Targeting inhibition of prognosis-related lipid metabolism genes including CYP19A1 enhances immunotherapeutic response in colon cancer.
Liu L; Mo M; Chen X; Chao D; Zhang Y; Chen X; Wang Y; Zhang N; He N; Yuan X; Chen H; Yang J
J Exp Clin Cancer Res; 2023 Apr; 42(1):85. PubMed ID: 37055842
[TBL] [Abstract][Full Text] [Related]
18. Cooperative Immune-Mediated Mechanisms of the HDAC Inhibitor Entinostat, an IL15 Superagonist, and a Cancer Vaccine Effectively Synergize as a Novel Cancer Therapy.
Hicks KC; Knudson KM; Lee KL; Hamilton DH; Hodge JW; Figg WD; Ordentlich P; Jones FR; Rabizadeh S; Soon-Shiong P; Schlom J; Gameiro SR
Clin Cancer Res; 2020 Feb; 26(3):704-716. PubMed ID: 31645354
[TBL] [Abstract][Full Text] [Related]
19. Small interfering RNA for cancer treatment: overcoming hurdles in delivery.
Charbe NB; Amnerkar ND; Ramesh B; Tambuwala MM; Bakshi HA; Aljabali AAA; Khadse SC; Satheeshkumar R; Satija S; Metha M; Chellappan DK; Shrivastava G; Gupta G; Negi P; Dua K; Zacconi FC
Acta Pharm Sin B; 2020 Nov; 10(11):2075-2109. PubMed ID: 33304780
[TBL] [Abstract][Full Text] [Related]
20. Blockage of the IDO1 pathway by charge-switchable nanoparticles amplifies immunogenic cell death for enhanced cancer immunotherapy.
Shi M; Zhang J; Wang Y; Han Y; Zhao X; Hu H; Qiao M; Chen D
Acta Biomater; 2022 Sep; 150():353-366. PubMed ID: 35843594
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
